Okada S, Saito E, Ogawa T, Sadamoto K, Kinoshita M
4th Department of Medicine, Toho University School of Medicine, Tokyo, Japan.
Eur Neurol. 1995;35(2):99-103. doi: 10.1159/000117101.
Exophthalmos and thyrotropin-inhibitory immunoglobulin (TBII) were examined in myasthenia gravis (MG) patients with normal thyroid function. Exophthalmos was found in 7 of 31 (22.6%) MG patients, and TBII was detected in 4 of 21 (19.0%) MG patients. The grades of exophthalmos did not decrease after extraocular muscle weakness was improved by treatment. Patients with MG whose diplopia was Tensilon unresponsive were only found among those with exophthalmos. TBII was more frequently detected in MG patients with exophthalmos than in those without. The present study revealed that exophthalmos is not rare in MG patients, even if they do not show any signs of Graves' disease other than exophthalmos and their thyroid functions are within the normal limit. The presence of TBII in MG patients may relate to the development of exophthalmos, and exophthalmos itself might enhance ocular symptoms of MG.
对甲状腺功能正常的重症肌无力（MG）患者进行了突眼和促甲状腺素抑制性免疫球蛋白（TBII）检测。在31例MG患者中，有7例（22.6%）出现突眼；在21例MG患者中，有4例（19.0%）检测到TBII。治疗改善眼外肌无力后，突眼程度并未减轻。仅在有突眼的MG患者中发现对腾喜龙无反应的复视患者。与无突眼的MG患者相比，有突眼的MG患者中更常检测到TBII。本研究表明，即使MG患者除突眼外无任何格雷夫斯病迹象且甲状腺功能在正常范围内，突眼在MG患者中也并不罕见。MG患者中TBII的存在可能与突眼的发生有关，突眼本身可能会加重MG的眼部症状。
